Here is part of the Chinese announcement. Translated by google:
Shenzhen Hai Purui Pharmaceutical
Group Co., Ltd
On the use of its own funds
Resver
logix Corp.
An announcement of investment
The Company and all the members of the Board of Directors guarantee that the contents of the information disclosure are true, accurate and complete.
False record, misleading statement or material omission.
First, the investment overview
1
, Before the investment, the company holds
RVX
Issued
14,603,333
Shares of ordinary shares, the proportion of shares held
12.74%
The The company also owns
RVX
Of the patented product
RVX-208
In mainland China, Hong Kong, Macau and Taiwan
Exclusive market license.
2
, The company
2017
year
10
month
13
Day with
RVX
Signed an equity subscription agreement
The
RVX
The new issue is the highest
Does not exceed
61,000,000
Shares of ordinary shares, the issue price is
1.44
Canadian dollar
/
Shares, and in accordance with each ordinary shares
Corresponding issue
0.082759
Share of shares
Warrants
The The company intends to own funds
Does not exceed
8,700
Million card subscription
RVX
New issue is not exceeded
60,416,667
Shares of common stock, and get the corresponding warrants.
3
, This investment is subject to approval by the Toronto Stock Exchange, as well as the Board of Directors and the relevant government
Door approval.
4
, This investment does not constitute a related party transactions and major asset restructuring.
5
, According to relevant laws and regulations, rules and company chapters
Procedures and other provisions, the investment in the board of directors Fan Fan
Within the scope, no need to submit to the shareholders meeting for approval
The
Second, the basic situation of the subject matter of the transaction
1
, The name of the investment target:
Resve
rlogix
Corp.
Registered address:
Richard Calgary, Canada
SW482
